Formoterol/glycopyrrolate - Pearl Therapeutics

Drug Profile

Formoterol/glycopyrrolate - Pearl Therapeutics

Alternative Names: BEVESPI AEROSPHERE; GFF MDI; Glycopyrrolate/formoterol; PT-003; PT001/PT005; PT003-GFF; PT005/PT001

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Pearl Therapeutics
  • Class Antiasthmatics; Antispasmodics; Bronchodilators; Ethanolamines; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 25 Sep 2017 Preregistration for Chronic obstructive pulmonary disease in European Union (Inhalation)
  • 25 Sep 2017 EMA accepts MAA for formoterol/glycopyrrolate for chronic obstructive pulmonary disease for review
  • 31 Aug 2017 Pearl Therapeutics completes the phase III PINNACLE 4 trial in Chronic obstructive pulmonary disease in China, Japan, South Korea, Taiwan, Hungary, Poland, Czech Republic, Germany, United Kingdom, USA (Inhalation) (NCT02343458) (EudraCT2014-004712-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top